Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study

doi:10.3748/wjg.v23.i22.4102

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 22

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10849)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

650

WORD

249

HTML

6577

Figures (1-2)

196

Tables (1-5)

206

Sum=7878

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1040

Download

1931

Sum=2971

Jun 14, 2017 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Jun 14, 2017; 23(22): 4102-4111
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4102

Open in New Tab Full Size Figure Download Figure

Figure 1 Serum alanine aminotransferase and bilirubin plot in 251 consecutive IBD patients (all measurements in all patients, values expressed in times the upper limit of normal. ADA: Adalimumab; AZA: Azathioprine; IFX: Infliximab; no-IS: No Immunosuppression.

Open in New Tab Full Size Figure Download Figure

Figure 2 Serum alanine aminotransferase and alkaline phosphatase plot in 251 consecutive inflammatory bowel disease patients (all measurements in all patients, values expressed in times the upper limit of normal. ADA: Adalimumab; AZA: Azathioprine; IFX: Infliximab; no-IS: No immunosuppression.

Citation: Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, Toth J, Krajcovicova A, Payer J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23(22): 4102-4111
URL: https://www.wjgnet.com/1007-9327/full/v23/i22/4102.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i22.4102